Because the clinical benefit of CDK4/6 or PARP-1 targeted inhibition as respective monotherapies might be, as also shown in other tumor entities [19,20], limited for BLCA, suitable combination therapies for these compounds are necessary for sufficient therapeutic efficiency. This evidence concerns the gene PARP1 and bladder transitional cell carcinoma.